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Perineural invasion pre-RP: Yes, 11 (6.92%); No, 108 (67.92%) and 
unknown, 40 (25.16%). Post-RP PSA: < 0.20 ng/ml: 88 (55.34%), ≥ 0.20 
ng/ml (Permanently Detectable-PSA or PD-PSA): 55 (34.59%) and 
unknown: 16 (10.06%). Initial EBRT intention: Adjuvant: 46 (28.93%), 
Salvage: 113 (71.07%). Corrected EBRT intention: Adjuvant: 23 
(14.46%), Salvage: 136 (85.53%), with 23 patients with a PD-PSA (Post-
RP PSA > 0.20 ng/ml). Androgenic deprivation: Yes 47 (29.56%), No: 
112 (70.44%). Time from BF diagnosis to EBRT referral: Mean: 16.95 
months (m), median: 5.50 m, range [0-147 m]. Pre-EBRT PSA: <1 
ng/ml: 84 (52.83%), ≥1 ng/ml: 56 (35.22%), unknown: 19 (11.95%). 
EBRT Dose: 66 Gy: 24 (19.74%), 70 Gy: 79 (59,21%), 72-74 Gy: 45 
(21,05%), interrupted: 1 (0,63%). After a median-FU of 23 m, 101 
patients (63.52%) remains free of biochemical progression, 16 patients 
(10.06%) have BP and 42 (26.42%) are lost. Perineural invasion pre-RP 
is a predictor of poor prognosis after post-RP EBRT (p = 0.012). There 
is a statistically significant benefit in BFFS when RT dose is >72 Gy (p 
= 0.048), moreover when patients with PD-PSA are analyzed (p = 
0.010). The beneficial effect of increased dose is maintained when 
pre-EBRT PSA is <1 ng/ml (p = 0.008), but not when pre-EBRT PSA is > 
1 ng/ml (p = 0.139). 
Conclusions: The majority of patients remitted to our Service for 
EBRT treatment, followed the criteria established for salvage-
treatment. Perineural invasion before RT appeared as a bad prognosis 
factor. Doses over 72 Gy were associated to longer times to BFFS, 
especially in those patients with PD-PSA. This effect was observed 
even when PSE pre.EBRT is < 1 ng/ml, but was not observed when that 
value was > 1 ng/ml. 
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Purpose/Objective: Single-institution single-arm prospective study. 
Endpoint: To assess acute toxicity (to exclude >5% of men have grade 
3 GU or any grade 3 GI). 
Materials and Methods: Since 9-2012 seven NCCN intermediate-high 
prostate cancer patients were treated with helical tomotherapy. 
Exclusion criteria: Gleason score ≥8, PSA >20, cT3b-4, IPSS≥20, history 
of acute urinary retention, difficulty following directions.CT-
simulation using Combifix™ with empty rectum and 200 ml bladder 
filled through urine catheter. CTV included prostate and seminal 
vesicles. PTV margins were 3-10 mm. Total dose to 95% PTV was 45.2 
Gy in 8 fx of 5.65 Gy on alternate days. EQD2= 78.2 Gy (a/b3) or 92.3 
Gy (a/b1.5). Rectal constraints: V43 <10%, V40 <15%, V37 <20%, V34 
<30%, V28 <40%. MVCT for on-line correction in every fraction. 
Cleansing enema prior each fraction. Bladder volume during 
irradiation was controlled through: 1) bladder filling using urine 
catheter (1st patient), or 2) measuring urine volume right after every 
fraction to provide feedback about the delay between water intake 
and treatment. All men received neoadjuvant-concomitant ADT. 
Results: Patients characteristics are cT1c-3a, Gleason score 6-7, PSA 
8-14 ng/ml.,IPSS 5-8. CTCAE acute GI toxicity: 0/7 grade 2, 2/7 grade 
1 (rectal discomfort) and 5/7 grade 0. GU figures: 1/7 grade 2 
(dysuria), 4/7 grade 1 (frequency,urgency, nocturia) and 2/7 grade 0. 
GU grade 2 toxicity was related to catheterisation manoeuvres in the 
first patient, so that dysuria resolved when bladder volume was 
controlled measuring urine. For the remaining patients the latter 
procedure was used. In total, after 56 MVCT, the mean and SD 
corrections in vertical direction were 0.58±2.4 mm (maximum 
corrections 4±1 mm).  
Conclusions: Tomotherapy-delivered extreme hypofractionated 
radiotherapy in selected prostate cancer patients shows promising 
early results. Our findings suggest that bladder catheterization should 
be avoided. 
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Purpose/Objective: The objective of this study was to evaluate the 
safety, feasibility, side-effect profile, and proof of concept of 
external beam radiotherapy (EBRT) with or without high-dose-rate 
brachytherapy (HDR-BT) for salvage of local-only failure after primary 
EBRT for prostate cancer. 
Materials and Methods: Fourteen patients (median age=68 years) with 
local-only recurrence after primary EBRT with or without BT were 
considered eligible for reirradiation. Median delivered dose in 2 Gy-
fractions at the first RT (NTD2Gy, α/β ratio=1.5 Gy) was 74 Gy (66-
98.4) using 2D- (n=4) or 3D-conformal RT (n=10). Pelvic RT and a boost 
with HDR-BT were used in 6 and 2 patients, respectively, with 
androgen deprivation therapy (ADT) used in 9 (median duration=6 
months). At relapse, all patients presented with a local failure-only as 
documented by prostate biopsies (n=11) and/or radiological imaging 
including erMRI (n=11) or PET/CT (n=12). Median time between the 
first RTand the re-irradiation was 6.1 years (range, 4.7-10.2). PSA at 
re-irradiation ranged between 4.8 and 116 ng/ml (median, 26.7 
ng/ml). Gastrointestinal (GI) and genitourinary (GU) toxicity free-
survival and biochemical relapse-free (bRFS), local relapse-free 
(LRFS), distant metastasis-free (DMFS) and cancer-specific(CSS) 
survivals were estimated with the Kaplan-Meier method  
Results: Between 2003 and 2008, a median NTD2Gy of 85.1 Gy (70-
93.4) was delivered as salvage RT to the prostate ± seminal vesicles 
(SV) with EBRT only (n=4) or EBRT + HDR-BT (n=10), adding ADT in 12 
patients (median,12 months). Median delivered dose to the whole 
prostate ± SV was 45 Gy (44-72), with a boost delivered to the local 
relapse only, using HDR-BT or IMRT in 10 and 3 patients, respectively. 
One patient was treated to the whole prostate with 72 Gy in 2.25 Gy 
per fraction using IMRT. No Grade 3 or more acute GI or GU toxicities 
were observed during RT or 6-weeks after the end of RT. At a median 
FU of 70 months (range, 48-121), the 5-yr Grade ≥ 3 GU and GI 
toxicity-free survival figures were 70±12.4% and 42.9±13.2%, 
respectively. Three patients presented with combined Grade 4 GU/GI 
toxicity consisting of rectal-prostatic and/or vesico-rectal fistula 
formation. One patient presented with rectal necrosis requiring 
colostomy. Ten and 8 patients presented with biochemical and local 
relapse, respectively. The 5-yrs bRFS, LRFS, DMFS and CSS were 
35.7±12.8%, 50.0±13.4%, 85.7±9.4% and 100%, respectively.  
Conclusions: EBRT using 3D-CRT and/or IMRT ± HDR BT as salvage 
option for patients with local recurrence after initial RT for prostate 
cancer may result in a relatively poor long-term biochemical and local 
control witha fairly high rate of severe radiation-induced side-effects. 
Alternative salvage treatment modalities should be first 
recommended, leaving reirradiation as an exceptional option only to 
be considered in very carefully selected cases. 
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Purpose/Objective: To compare acute urinary and anorectal toxicities 
in prostate cancer patients undergoing intensity modulated radiation 
therapy (IMRT) with those undergoing three dimensional conformal 
radiation therapy (3D-CRT). 
Materials and Methods: Between April 2010 and March 2012, 129 
consecutive patients who underwent definitive external beam 
radiation therapy for prostate cancer were evaluated. Patients were 
retrospectively assigned to two groups: IMRT (N = 53) and 3D-CRT (N = 
76). Acute urinary and anorectal toxicities were investigated using 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 
IMRT was delivered with 74Gy/37 fractions by the 7 field step-and-
shoot technique; 3DCRT was delivered with 70Gy/35fractions by the 
static 4-6 multiple field technique. Acute toxicity was defined as the 
worst event within three months after completing radiation therapy. 
The two groups' characteristics and treatment factors were compared 
by t-test and Chi-square or Fisher’s exact test, as appropriate. The 
acute toxicity grades between the groups were compared by Mann-
Whitney U-test.  
Results: Age, National Comprehensive Cancer Network (NCCN) risk 
groups, and total doses were significantly different between the two 
groups. There were no grade 3 or higher urinary or anorectal acute 
toxicities. Although there was no significant difference in urinary 
acute toxicity, there were significant differences for rectal mucositis 
(p=0.002) and anal mucositis (p=0.011) for anorectal acute toxicity 
between the two groups, with milder toxicity in the IMRT group. 
Conclusions: Acute anorectal toxicity in prostate cancer patients 
treated with IMRT is significantly milder compared to those treated 
with 3D-CRT.  
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